Scientists have identified 3 gene variants of HOXD9, which can help explain the development of ovarian cancer.
Scientists at the Keck School of Medicine, University of Southern California, have identified 3 gene variants of HOXD9, which can help explain the development of the fourth most common cause of cancer in the United States, ovarian cancer.
"By finding these genetic markers, we begin to understand more about the biology of the disease itself," said Dr Simon Gayther, the corresponding author on the manuscript that was published in Nature Genetics, in a statement.
The retrospective study was conducted in 1644 women diagnosed with mucinous ovarian cancer and 21000 women without the disease, under the umbrella of the Collaborative Oncological Gene-environment Study, created to determine the risks of breast, ovarian, and prostate cancer.
Read more on ScienceDaily: http://bit.ly/1IiNBKp
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More